Methotrexate, Glucarpidase, and Leucovorin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma - Related Studies - ClinicalTrials.gov

Skip to Main Content

ClinicalTrials.gov

Beta test our new site.

(NLM Technical Bulletin)

Home Search Study Topics Glossary


	Full Text View


	Tabular View


	No Study Results Posted


	Related Studies

Methotrexate, Glucarpidase, and Leucovorin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma

The recruitment status of this study is unknown because the information has not been verified recently.

Verified November 2008 by National Cancer Institute (NCI).
Recruitment status was Recruiting

Study NCT00727831 Information provided by National Cancer Institute (NCI)

First Received on August 1, 2008. Last Updated on March 10, 2010 History of Changes

Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:

Conditions listed in this trial

Chemotherapeutic Agent Toxicity
Lymphoma
Mucositis
Neurotoxicity

Additional conditions recognized in this trial

Neurotoxicity Syndromes

More general conditions related to this trial

Digestive System Diseases
Gastroenteritis
Gastrointestinal Diseases
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoproliferative Disorders
Mouth Diseases
Neoplasms
Neoplasms by Histologic Type
Nervous System Diseases
Poisoning
Stomatognathic Diseases
Substance-Related Disorders

Interventions listed in this trial

glucarpidase
leucovorin calcium
methotrexate
laboratory biomarker analysis
quality-of-life assessment
radiation therapy

Additional drug interventions recognized in this trial

Leucovorin
Levoleucovorin

Sponsors listed in this trial

Cancer Research UK

Back to top of Main Content